Sumitomo Pharma | Sustainability Performance

https://www.sumitomo-pharma.com/

Develops and markets pharmaceutical products.

1897

Japan

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#10009

Overall

#471

in Japan

#244

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

103 out of 312

Overview

Environmental

Carbon emissionsEnergy consumptionWaste managementWater managementAir and land impactNature and biodiversityNature riskClimate risk

Social

Diversity and inclusionPay gapsHealth and safetyExternalities

Governance

TargetsSDG ImpactESG scores and exclusionsB-corp & CDP

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Rici Healthcare

Japan, Hospital & Health Care, Hospital & Health Care

Santen Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Takeda Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Renewable energy

13% 2024

Laggard

Waste generated

7.8K tonnes, 2024

Laggard

Female engagement

51% 2024

Aligned

Externalities

3.3M $, 2025

Laggard

Market cap

96.6T $, 2026▲0.2% YoY

Revenue

3.0B $, 2026▲12% YoY

R&D intensity

9.71% 2026

Intensity

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Energy consumption (direct) intensity (MWh /$M)

Water consumption intensity (m³ /$M)

Industry Benchmark

126.5

B/M 114.3

89.7

B/M 35.7

224.0

B/M 219.7

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Sumitomo Pharma Co Ltd (formerly Sumitomo Dainippon Pharma), Japanese pharma major, has faced multiple US class actions over alleged inadequate disclosure of Latuda generic competition affecting Sumitomo Pharma's US revenue, plus the contested 2024 USD 800+ million Myovant Sciences acquisition integration challenges and sustained share price collapse affecting Japanese institutional shareholders.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******

KPI	Metric	Year
	2014	2015	2016	2017	2018	Benchmark
*******	*******	-	-	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2020	2021	2022	2023	2024	Benchmark
*******	*******	-	-	*******	*******	*******	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	-	-	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Air pollution

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2020	2021	2022	2023	2024	Benchmark
*******	*******	-	-	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SBTi targets and commitments

Target	Status	Temperature alignment	Year
Near-term target	Targets set	1.5°C	FY2030
Long-term target	Not disclosed	-	-
Net-zero	Not disclosed	-	-
Business Ambition 1.5°C	Not disclosed	-	-

Target details

Sumitomo Pharma Co., Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2020 base year. Sumitomo Pharma Co., Ltd. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services 25% within the same timeframe.

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Sumitomo Pharma Co Ltd (formerly Sumitomo Dainippon Pharma), Japanese pharma major, has faced multiple US class actions over alleged inadequate disclosure of Latuda generic competition affecting Sumitomo Pharma's US revenue, plus the contested 2024 USD 800+ million Myovant Sciences acquisition integration challenges and sustained share price collapse affecting Japanese institutional shareholders.

Sumitomo Pharma | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

SBTi targets and commitments

Target details

Overall score

Environment

Social

Governance

Exclusion screening

CDP Scores

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Sumitomo Pharma | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable energy

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package